Gooc, Geneveve T.
HRN: 22-96-41 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
05/11/2023
CO-AMOXICLAV 625MG (TAB)
05/11/2023
05/18/2023
ORAL
625mg
BID
Aub; Uti
Waiting Final Action
Indication: Empiric Type of Infection: Reproductive Tract Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes